Number 580 • February 2016

Product supply shortages addressed for *Alberta*Drug Benefit List (ADBL)

Alberta Blue Cross has been advised by Apotex Inc. that the shortage of Apo-Feno-Super 160 mg Tablet (DIN 02246860) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **February 29, 2016.**

FENOFIBRATE

160 MG CAPSULE / TABLET

00002246860	APO-FENO-SUPER (TABLET)	APX	\$ 0.2723
00002356589	FENOFIBRATE-S (TABLET)	SNS	\$ 0.2723
00002288052	SANDOZ FENOFIBRATE S (TABLET)	SDZ	\$ 0.2723
00002241602	LIPIDIL SUPRA (TABLET)	FAB	\$ 1.2823

Alberta Blue Cross has been advised by Mylan Pharmaceuticals ULC that the shortage of Mylan-Bupropion XL 300 mg Extended-Release Tablet (DIN 02382083) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **March 1, 2016.**

BUPROPION HCL

300 MG EXTENDED-RELEASE TABLET

00002382083	MYLAN-BUPROPION XL	MYP	\$ 0.7963
00002275104	WELLBUTRIN XL	VCL	\$ 1.1454

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • **403-294-4041** (Calgary and area) • **1-800-361-9632** (toll free) **FAX 780-498-8406** (Edmonton and area) • **FAX 1-877-305-9911** (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims. **Visit https://www.ab.bluecross.ca/providers/pharmacy-home.php**





